LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.

Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xinhong Wu(Jiangnan University), Deyong Zhang(Hunan University), Changping Shan(Affiliated Hospital of Jining Medical University), Fuming Qiu(Second Affiliated Hospital of Zhejiang University), Changlu Hu(Anhui Provincial Hospital), Tao Sun(Wuhan University), Xinlan Liu(Yunnan Agricultural University), Xiaohua Zeng(Chongqing Cancer Hospital), Zhongsheng Tong(Institute of Oncology NN Petrov), Tong Li(Second Affiliated Hospital of Xi'an Jiaotong University), Yang Luo(Chongqing University of Posts and Telecommunications), Shusen Wang(Sun Yat-sen University), Xiaojia Wang(Wenzhou Medical University), Qingyuan Zhang(Harbin Medical University), Zhendong Chen(Anhui Medical University), Bing Zhao(Xinjiang Medical University), Hongyan Jia(Shanxi Medical University), Xi Yan(Sichuan University), Yumin Yao(Liaocheng People's Hospital)
Journal of Clinical Oncology
June 1, 2023
10.1200/jco.2023.41.16_suppl.1017
Cited by 4

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743